14 February 2025
EMADOC-1700519818-1896425
Committee for Veterinary Medicinal Products (CVMP)

Summary of opinion[1] (post-authorisation)

Simparica Trio

International non-proprietary name (INN): sarolaner / moxidectin / pyrantel embonate

On 12 February 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Simparica Trio. The marketing authorisation holder for this veterinary medicinal product is Zoetis Belgium.

Simparica Trio is currently authorised as chewable tablets for use in dogs. The variation concerns change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one: reduction of the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* for one month after treatment.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union